Annovis Bio, Inc. (ANVS)
| Previous close | 6.11 |
| Open | 6.20 |
| Bid | 5.84 x 900 |
| Ask | 5.88 x 800 |
| Day's range | 5.60 - 6.16 |
| 52-week range | 5.23 - 22.49 |
| Volume | |
| Avg. volume | 437,868 |
| Market cap | 63.925M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
- Reuters
UPDATE 3-Annovis tumbles as Alzheimer's treatment misses in mid-stage study
Annovis Bio's on Monday reported data that showed its Alzheimer's disease drug failed to show statistical significance in meeting the goals of a mid-stage trial sending its shares tumbling as much as 60%. The trial tested the drug buntanetap in patients with mild-to-moderate Alzheimer's disease (AD) along two scales assessing cognition and cognitive dysfunction. In a press release, the company said a "post-hoc" analysis of the trial data had shown statistically significant results in improving cognition function scores along an Alzheimer's disease scale in a subgroup of patients who had mild disease and who tested positive for certain disease biomarkers.
- Zacks
Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 198% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
